TDMS Study 05156-06 Pathology Tables
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
CORE STUDY
Facility: Battelle Northwest
Chemical CAS #: 10026-24-1
Lock Date: 07/12/94
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 5 3 5 6
Moribund Sacrifice 11 10 13 16
Survivors
Terminal Sacrifice 34 37 32 28
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (43) (43) (38) (43)
Intestine Large, Cecum (49) (49) (48) (47)
Leiomyoma 1 (2%)
Intestine Small, Duodenum (47) (48) (47) (45)
Intestine Small, Jejunum (48) (49) (47) (44)
Hemangiosarcoma 1 (2%)
Intestine Small, Ileum (48) (48) (47) (45)
Liver (50) (50) (50) (49)
Hemangiosarcoma 1 (2%) 3 (6%)
Hepatocellular Carcinoma 12 (24%) 9 (18%) 16 (32%) 4 (8%)
Hepatocellular Adenoma 7 (14%) 7 (14%) 11 (22%) 9 (18%)
Hepatocellular Adenoma, Multiple 1 (2%) 3 (6%) 2 (4%) 3 (6%)
Hepatocholangiocarcinoma 2 (4%)
Histiocytic Sarcoma 3 (6%) 2 (4%) 2 (4%)
Mesentery (10) (12) (8) (7)
Hemangioma 1 (14%)
Hemangiosarcoma 1 (8%) 1 (13%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (10%)
Histiocytic Sarcoma 1 (8%)
Sarcoma 1 (10%)
Pancreas (50) (50) (49) (49)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (49) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (49) (50)
Muscularis, Serosa, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (49) (50) (49) (49)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (50) (49) (49)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (48) (47) (47) (48)
Pars Distalis, Adenoma 11 (23%) 8 (17%) 7 (15%) 8 (17%)
Thyroid Gland (50) (49) (49) (49)
Follicular Cell, Adenoma 3 (6%) 5 (10%)
Follicular Cell, Carcinoma 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (48) (49) (49) (48)
Arrhenoblastoma Benign 1 (2%)
Cystadenocarcinoma 1 (2%)
Cystadenoma 2 (4%) 3 (6%) 3 (6%) 3 (6%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Luteoma 1 (2%) 1 (2%)
Teratoma Benign 1 (2%) 1 (2%) 1 (2%)
Yolk Sac Carcinoma 1 (2%)
Uterus (50) (50) (49) (49)
Hemangioma 1 (2%) 2 (4%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 2 (4%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymph Node (3) (6) (3) (4)
Histiocytic Sarcoma 1 (33%)
Lumbar, Histiocytic Sarcoma 1 (33%)
Renal, Histiocytic Sarcoma 2 (67%)
Lymph Node, Bronchial (30) (34) (27) (35)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (7%)
Histiocytic Sarcoma 1 (3%) 1 (3%) 1 (3%)
Lymph Node, Mandibular (37) (37) (36) (36)
Histiocytic Sarcoma 2 (5%) 2 (5%) 1 (3%)
Lymph Node, Mesenteric (46) (45) (46) (44)
Histiocytic Sarcoma 3 (7%) 2 (4%) 1 (2%)
Lymph Node, Mediastinal (41) (36) (28) (34)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (5%)
Histiocytic Sarcoma 3 (7%) 2 (6%) 1 (3%)
Spleen (50) (50) (49) (49)
Histiocytic Sarcoma 3 (6%) 2 (4%) 1 (2%)
Thymus (41) (44) (41) (41)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (47) (50) (50) (50)
Adenoma 1 (2%)
Carcinoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Skin (49) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Mast Cell Tumor Benign 1 (2%)
Subcutaneous Tissue, Sarcoma 6 (12%) 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (2) (1)
Sarcoma 1 (50%) 1 (100%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 5 (10%) 8 (16%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%) 4 (8%) 9 (18%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 5 (10%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%)
Histiocytic Sarcoma 3 (6%) 2 (4%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Nose (50) (50) (49) (48)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (2) (1)
Adenoma 2 (100%) 2 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%)
Urinary Bladder (48) (47) (45) (46)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 2 (4%) 3 (6%)
Lymphoma Malignant 4 (8%) 7 (14%) 7 (14%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 41 43 39
Total Primary Neoplasms 70 61 76 68
Total Animals with Benign Neoplasms 25 32 27 27
Total Benign Neoplasms 36 36 38 44
Total Animals with Malignant Neoplasms 27 22 31 21
Total Malignant Neoplasms 34 25 38 24
Total Animals with Metastatic Neoplasms 6 5 3
Total Metastatic Neoplasm 12 5 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 19 16 17 23
Accidently Killed 1 1
Natural Death 8 3 9 6
Survivors
Terminal Sacrifice 22 31 24 20
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (45) (49) (45) (46)
Intestine Small, Duodenum (45) (49) (42) (45)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (45) (48) (42) (45)
Carcinoma 1 (2%)
Intestine Small, Ileum (45) (49) (43) (44)
Liver (50) (50) (50) (50)
Hemangiosarcoma 2 (4%) 4 (8%) 8 (16%) 7 (14%)
Hepatoblastoma 4 (8%) 2 (4%) 2 (4%)
Hepatocellular Carcinoma 16 (32%) 32 (64%) 29 (58%) 26 (52%)
Hepatocellular Carcinoma, Multiple 7 (14%) 1 (2%) 1 (2%) 4 (8%)
Hepatocellular Adenoma 14 (28%) 12 (24%) 16 (32%) 6 (12%)
Hepatocellular Adenoma, Multiple 8 (16%) 9 (18%) 9 (18%) 7 (14%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Mesentery (3) (4) (5) (4)
Hemangiosarcoma 1 (25%) 1 (25%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (20%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (33%)
Sarcoma, Metastatic, Liver 1 (25%)
Pancreas (48) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Liver 1 (2%)
Stomach, Forestomach (49) (50) (50) (50)
Sarcoma, Metastatic, Liver 1 (2%)
Squamous Cell Carcinoma 2 (4%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (48) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Serosa, Hepatocellular Carcinoma, Metastatic,
Liver 1 (2%)
Page 7
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 1 (2%)
Sarcoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Adrenal Medulla (48) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (48) (50) (49) (50)
Adenoma 1 (2%)
Thyroid Gland (49) (50) (50) (50)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
Tissue NOS (1) (1)
Hemangioma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (50) (50) (50)
Leiomyoma 1 (2%)
Testes (49) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%)
Lymph Node (1) (1) (2) (2)
Iliac, Sarcoma, Metastatic, Liver 1 (50%)
Renal, Histiocytic Sarcoma 1 (100%)
Page 8
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Bronchial (21) (24) (28) (25)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (4%)
Histiocytic Sarcoma 1 (5%)
Sarcoma, Metastatic, Liver 1 (4%)
Lymph Node, Mesenteric (49) (48) (43) (47)
Hemangiosarcoma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Liver 1 (2%)
Lymph Node, Mediastinal (43) (28) (31) (35)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Liver 1 (3%)
Spleen (47) (50) (49) (50)
Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (28) (31) (33) (28)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50) (49) (49)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Carcinoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Skeletal Muscle (1) (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 9 (18%) 9 (18%) 11 (22%) 13 (26%)
Alveolar/Bronchiolar Adenoma, Multiple 3 (6%) 2 (4%) 5 (10%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 5 (10%) 5 (10%) 9 (18%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 2 (4%) 2 (4%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 5 (10%) 5 (10%) 6 (12%) 7 (14%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (4) (4) (6)
Adenoma 4 (100%) 2 (50%) 2 (50%) 1 (17%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05156-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC COBALT SULFATE HEPTAHYDRATE Date: 07/03/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:41:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.3 1.0 3.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 48 47 46
Total Primary Neoplasms 77 94 92 95
Total Animals with Benign Neoplasms 30 30 30 27
Total Benign Neoplasms 38 39 42 35
Total Animals with Malignant Neoplasms 33 39 41 38
Total Malignant Neoplasms 39 55 50 60
Total Animals with Metastatic Neoplasms 7 6 7 9
Total Metastatic Neoplasm 14 6 7 21
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------